All In Biotech

Drug Trial Radar · NCT05638854

A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis

A Phase 1, 2-Part, Single Ascending Dose (SAD) Study to Evaluate the Safety and Pharmacokinetics (PK) of ZB002 in Healthy Volunteers (HVs) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety and PK of ZB002 in Participants With Rheumatoid Arthritis (RA)

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Dec 8, 2022

Primary completion

Feb 16, 2026

Study completion Feb 16, 2026

Sponsor

Lead sponsor
Zenas BioPharma (USA), LLCIndustry
Sponsor type
Industry
First posted
Dec 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This double-blind, randomized, placebo-controlled study will assess the safety and pharmacokinetics of ZB002 in healthy participants and in participants with rheumatoid arthritis (RA). The study consists of 2 parts. Part A: Single Ascending Dose (SAD), which will include only healthy volunteers. Part B: Multiple Ascending Dose (MAD), will commence after completion of the SAD study and will include RA participants.

Conditions

  • Healthy Volunteers
  • Rheumatoid Arthritis

Interventions

  • ZB002Drug

    ZB002 will be administered subcutaneously as per schedule specified in the respective arm.

  • PlaceboDrug

    Placebo will be administered subcutaneously as per schedule specified in the respective arm.

  • ZB002Drug

    ZB002 will be administered subcutaneously as per schedule specified in the respective arm.

  • PlaceboDrug

    Placebo will be administered subcutaneously as per schedule specified in the respective arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety and Tolerability in HVsTime frame: Day 1 through Day 120
  2. Part B: Safety and Tolerability of multiple doses of ZB002 in participants with RATime frame: Day 1 through Day 176

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Veritus Research

    Melbourne, Australia

  • NZCR New Zealand Clinical Research

    Christchurch, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.